Rosalind Rei has a background in science communication and business journalism. Before joining Generics Bulletin in 2022, she worked as a freelance writer and researcher covering sustainability, biotech, biomaterials, climate science, and carbon finance. She has also written and produced episodes on the history of science for the Harvard-based podcast Ministry of Ideas.
She holds a master’s in the history and philosophy of science and takes keen interests in political economy, ecology, and environment.
Latest From Rosalind Rei
Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.
Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.
Despite a quarter-on-quarter improvement, overall sales remain in the doldrums as Jubilant mounts a multi-pronged strategy to pull through the generics decline.
The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.
Medicines for Europe, along with EFPIA and the AESGP, say that the ‘polluter pays’ principle behind proposed new European rules on wastewater treatment would saddle pharmaceutical manufacturers with costs that “jeopardize patient access.”
JSR Life Science’s new business unit embarks on its first partnership with publicly listed Brazilian pharmaceutical.